McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for McKesson Corporation for the quarter and six months ended September 30, 2005 (Fiscal Year 2006). McKesson operates as a leading healthcare services company with three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies. The company's fiscal year ends on March 31.
Key Financial Metrics
| Metric | Quarter Ended Sep 30, 2005 | Six Months Ended Sep 30, 2005 |
|---|---|---|
| Revenues | $21,605 million | $42,663 million |
| Net Income | $167 million | $338 million |
| Diluted EPS | $0.53 | $1.08 |
| Gross Profit Margin | 4.14% | 4.26% |
| Operating Cash Flow | N/A (Quarterly not provided) | $2,009 million |
| Cash and Equivalents | $2,996 million | $2,996 million |
| Total Debt | $994 million (Long-term + Current) | $994 million |
| Working Capital | $3,675 million | $3,675 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8% for the quarter and 9% for the six-month period compared to the prior year, driven primarily by the Pharmaceutical Solutions segment (95% of total revenue).
- Profitability Surge: Net income increased 94% for the quarter and 35% for the six-month period. Diluted EPS rose 83% and 29%, respectively.
- Margin Expansion: Consolidated gross profit margins improved by 47 basis points for the quarter and 22 basis points for the six months, largely due to higher buy-side margins and generic drug sales in the Pharmaceutical segment.
- Acquisitions: The company acquired D&K Healthcare Resources ($478 million) and Medcon, Ltd. ($82 million) in August 2005, contributing to revenue and operating profit growth.
- Discontinued Operations: The company sold McKesson BioServices for net proceeds of $63 million, resulting in a $13 million after-tax gain.
Guidance, Outlook, Risks, and Unusual Items
- Securities Litigation: A significant contingent liability exists regarding the "Securities Litigation" stemming from 1999 accounting improprieties. As of September 30, 2005, the company has accrued $1,183 million. While management believes this is adequate, they note the possibility that ultimate costs could exceed this reserve. A $52 million charge was recorded in the first half of 2006 to increase reserves.
- Acquisition Integration: The company anticipates completing an evaluation of D&K's distribution center network in the third quarter of 2006, with potential restructuring costs to be incurred.
- Stock Repurchases: The Board approved a new $250 million stock repurchase plan in August 2005. The company repurchased 4.8 million shares in the quarter at an average price of $46.37.
- Accounting Changes: The company plans to adopt SFAS No. 123(R) in 2007, which will require recognizing the fair value of equity awards as an expense, potentially impacting future earnings.
- Forward-Looking Risks: Risks include the resolution of pending litigation, changes in healthcare reimbursement, consolidation of competitors, and the ability to integrate acquisitions.
Investor Verification Checklist
- Securities Litigation Reserve: Verify the adequacy of the $1.183 billion accrual against the status of pending cases and potential settlement outcomes.
- Working Capital Trends: Monitor the significant increase in operating cash flow ($2.0 billion for six months) to ensure it is sustainable and not solely due to timing of vendor payments or customer receipts.
- Acquisition Synergies: Track the integration progress and cost realization of the D&K and Medcon acquisitions against projected benefits.
- Margin Sustainability: Assess whether the improved gross margins in the Pharmaceutical segment are driven by sustainable factors (e.g., generic mix) or one-time items (e.g., antitrust settlements).
- Debt Covenants: Confirm continued compliance with the debt-to-capital ratio covenant (currently 14.5% vs. 56.5% limit) given the company's leverage and cash position.